Century Therapeutics, Inc.

NasdaqCM:IPSC Stock Report

Market Cap: US$413.0m

Century Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:IPSC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Jun 26SellUS$3,692Douglas CarrIndividual1,654US$2.23
12 Jun 26SellUS$5,767Gregory RussottiIndividual2,584US$2.23
08 Jun 26SellUS$526Douglas CarrIndividual249US$2.11
08 Jun 26SellUS$1,106Gregory RussottiIndividual524US$2.11
04 May 26SellUS$618Douglas CarrIndividual264US$2.34
12 Mar 26SellUS$25,684Gregory RussottiIndividual10,076US$2.55
12 Mar 26SellUS$17,953Douglas CarrIndividual7,043US$2.55
09 Mar 26SellUS$1,215Gregory RussottiIndividual479US$2.54
09 Mar 26SellUS$626Douglas CarrIndividual247US$2.54
03 Feb 26SellUS$589Douglas CarrIndividual323US$1.82
22 Dec 25BuyUS$49,252Chad CowanIndividual58,060US$0.85
12 Dec 25BuyUS$30,352Brent PfeiffenbergerIndividual52,000US$0.58
08 Dec 25SellUS$137Douglas CarrIndividual257US$0.53
08 Dec 25SellUS$280Gregory RussottiIndividual526US$0.53
20 Nov 25SellUS$2,736Chad CowanIndividual5,462US$0.50
19 Nov 25BuyUS$17,329Brent PfeiffenbergerIndividual35,000US$0.50
17 Nov 25SellUS$14,735Brent PfeiffenbergerIndividual32,456US$0.45
03 Nov 25SellUS$171Douglas CarrIndividual292US$0.59
08 Sep 25SellUS$270Gregory RussottiIndividual539US$0.50
08 Sep 25SellUS$244Brent PfeiffenbergerIndividual488US$0.50
08 Sep 25SellUS$132Douglas CarrIndividual263US$0.50
04 Aug 25SellUS$158Douglas CarrIndividual296US$0.53

Insider Trading Volume

Insider Buying: IPSC insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of IPSC?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders5,696,1653.16%
General Public11,493,1316.37%
Public Companies19,631,04510.9%
VC/PE Firms57,162,71431.7%
Institutions86,371,75447.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 109.3%.

Top Shareholders

Top 25 shareholders own 87.48% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.84%
RA Capital Management, L.P.
17,754,430US$40.7m0%0.5%
9.84%
TCG Crossover Management, LLC
17,754,430US$40.7m0%1.02%
7.03%
Bayer Aktiengesellschaft
12,675,838US$29.0m0%2.3%
6.75%
Versant Venture Management, LLC
12,166,109US$27.9m0%18.91%
5.26%
Deep Track Capital, LP
9,487,745US$21.7m0%0.36%
4.82%
RTW Investments, LP
8,695,652US$19.9m0%0.18%
4.82%
Commodore Capital LP
8,695,652US$19.9m0%0.95%
4.82%
VR Management, LLC
8,695,652US$19.9m0%0.6%
3.86%
FUJIFILM Holdings Corporation
6,955,207US$15.9m0%10.53%
3.31%
Point72 Asset Management, L.P.
5,964,678US$13.7m0.05%0.02%
3.15%
Vanguard Capital Management, LLC
5,686,204US$13.0m0%no data
2.78%
Balyasny Asset Management L.P.
5,017,733US$11.5m0%0.02%
2.59%
Millennium Management LLC
4,667,063US$10.7m665%0.01%
2.41%
Seven Fleet Capital Management LP
4,347,826US$10.0m0%3.02%
2.25%
Spruce Street Capital LP
4,059,054US$9.3m186%2.07%
2.1%
Adage Capital Management, L.P.
3,789,538US$8.7m106%0.01%
2.03%
Brent Pfeiffenberger
3,665,474US$8.4m192%no data
1.76%
Boxer Capital Management, LLC
3,174,603US$7.3m0%0.77%
1.69%
Woodline Partners LP
3,043,478US$7.0m0%0.02%
1.36%
Trails Edge Capital Partners, LP
2,449,993US$5.6m0%1.16%
1.35%
Dafna Capital Management, LLC
2,434,353US$5.6m-12.9%1.16%
1.31%
Two Sigma Investments, LP
2,371,430US$5.4m58.5%no data
0.85%
BlackRock, Inc.
1,524,422US$3.5m153%no data
0.78%
Dv Trading, LLC
1,400,000US$3.2m0%0.26%
0.72%
Rock Springs Capital Management LP
1,304,347US$3.0m0%0.16%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/20 11:25
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Century Therapeutics, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Chen YangBofA Global Research
William MaughanCanaccord Genuity